Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 15/20 | 0.75 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.59 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.59 |
| ▸ | DRD2 | P14416 | 4/20 | 0.55 |
| ▸ | DRD4 | P21917 | 3/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.55 |
| ▸ | DRD3 | P35462 | 3/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7068005 | 0.93 | OPRM1 (0.84) | OPRM1OPRL1OPRK1DRD2DRD4 | |
| SCHEMBL6497509 | 0.89 | OPRM1 (0.82) | OPRM1OPRL1OPRK1DRD2DRD4 | |
| SCHEMBL6506818 | 0.88 | OPRM1 (0.72) | OPRM1OPRL1OPRK1DRD2DRD4 | |
| SCHEMBL6507445 | 0.87 | OPRM1 (0.71) | OPRM1OPRL1OPRK1DRD2DRD4 | |
| SCHEMBL6507448 | 0.87 | OPRM1 (0.71) | OPRM1OPRL1OPRK1DRD2DRD4 | |
| SCHEMBL6503296 | 0.85 | OPRM1 (0.73) | OPRM1OPRL1OPRK1DRD2DRD4 | |
| SCHEMBL6497859 | 0.85 | OPRM1 (0.84) | OPRM1OPRL1OPRK1DRD2DRD4 | |
| SCHEMBL6504180 | 0.85 | OPRM1 (0.76) | OPRM1OPRL1OPRK1DRD2DRD4 | |
| SCHEMBL6507053 | 0.84 | OPRM1 (0.72) | OPRM1OPRL1OPRK1DRD2DRD4 | |
| SCHEMBL6504792 | 0.84 | OPRM1 (0.72) | OPRM1OPRL1OPRK1DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846735-B2 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. (US) | 2014-09-30 | — | — | US | claimed |
| US-20140072532-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | MICRODOSE THERAPEUTX, INC. (US) | 2014-03-13 | — | — | US | claimed |
| US-8575205-B2 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. (US) | 2013-11-05 | — | — | US | claimed |
| US-20120183498-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | NITZ THEODORE J (US) | 2012-07-19 | — | — | US | claimed |
| US-20050288344-A1 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. | 2005-12-29 | — | — | US | claimed |
| US-8962667-B2 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | Microdose Therapeutix, Inc. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20140363395-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | MICRODOSE THERAPEUTX INC (US) | 2014-12-11 | — | — | US | disclosed |
| US-8846735-B2 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140072532-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | MICRODOSE THERAPEUTX, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-8575205-B2 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20120183498-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | NITZ THEODORE J (US) | 2012-07-19 | — | — | US | disclosed |
| US-8202896-B2 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20050288344-A1 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. | 2005-12-29 | — | — | US | disclosed |
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2005-06-30 | — | — | US | disclosed |
| WO-2003037271-A2 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS,INC. (US) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288344-A1 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | TTPA, HAVCR2, ZC3HAV1 | OPRM1 4658/4885OPRL1 4844/4885OPRK1 4748/4885 |
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | CCR8, CCL11, CCR5 | OPRM1 494/4885OPRL1 140/4885OPRK1 246/4885 |
| US-20140072532-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | TTPA, HAVCR2, ZC3HAV1 | OPRM1 4658/4885OPRL1 4844/4885OPRK1 4748/4885 |
| US-20140363395-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | TTPA, HAVCR2, ZC3HAV1 | OPRM1 4658/4885OPRL1 4844/4885OPRK1 4748/4885 |
| US-20120183498-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | TTPA, HAVCR2, ZC3HAV1 | OPRM1 4658/4885OPRL1 4844/4885OPRK1 4748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.